

## Chairs

### Prof. Dr. Günter J. Hämmerling (1)

Tumor Immunology Program D030  
German Cancer Research Center (DKFZ)

### PD Dr. rer. nat. Jan Dörrie (2)

RNA-group, Dept. Dermatology,  
Universitätsklinikum Erlangen

### Prof. Dr. Diana Dudziak (3)

Laboratory of DC-Biology,  
Dept. Dermatology,  
Universitätsklinikum Erlangen

## Invited Discussants

J. Auböck, A. Baur, C. Bogdan, C. Bosch-Voskens,  
B. Fleckenstein, P. Fritsch, M. Hertl, H. Hintner,  
W. Hohenberger, E. Jäger, J. Kalden, E. Kämpgen,  
J. Knop, M. Lutz, C. Maczek, M. Röllinghoff,  
N. Romani, N. M. Sixt, N. Schaft, G. Schett,  
M. Schmuth, E. Schultz, A. Steinkasserer,  
G. Stingl, J. Vera-González, K. Wolff

## General Information

### Local Organising Committee

Prof. Dr. med. Michael Sticherling  
Prof. Dr. rer. nat. Alexander Steinkasserer  
Frau Christine Luff  
Frau Kristin Reizenstein  
Frau Andrea Egloffstein  
Hautklinik, Universitätsklinikum Erlangen  
Ulmenweg 18, 91054 Erlangen  
Tel.: 09131-85 45871  
Fax: 09131-85 32710  
christine.luff@uk-erlangen.de


**Emergency Phone Number:**  
**+49 175 - 4230605**

### Registration

No registration fee

**Please register by e-mail till October 7th,  
for a guaranteed place**

mail to: christine.luff@uk-erlangen



Kartenausschnitt: © openstreetmap.org

### Hautklinik

Prof. Dr. med. univ. Gerold Schuler, Emeritus Professor

Ulmenweg 18 (Internistisches Zentrum) 91054 Erlangen  
www.hautklinik.uk-erlangen.de

Tel.: 09131 85-45871  
Fax: 09131 85-32710  
hautklinik@uk-erlangen.de

Zur besseren Lesbarkeit verwenden wir bei der Bezeichnung von Personengruppen die männliche Form; selbstverständlich sind dabei die weiblichen Mitglieder eingeschlossen.

Wenn Sie künftig keine Informationen mehr aus der Hautklinik des Uni-Klinikums Erlangen erhalten wollen, wenden Sie sich bitte an [hautklinik@uk-erlangen.de](mailto:hautklinik@uk-erlangen.de).

Herstellung: Uni-Klinikum Erlangen/Kommunikation, 91012 Erlangen

# Minisymposium Cancer Vaccines and Dendritic Cells

Saturday, October 12, 2019, 8.00 a.m. – 5 p.m.

Hotel Novotel Erlangen  
Hofmannstraße 34, 91052 Erlangen

Hautklinik

Zertifiziert  
mit  
**8**  
Punkten

CCC Comprehensive  
Cancer  
Center  
Erlangen-EMN  
Europäische Metropolregion Nürnberg

DZI Deutsches  
Zentrum  
Immuntherapie

Universitätsklinikum  
Erlangen

## Foreword

### Dear colleagues and friends,

therapeutic cancer vaccines have undergone a roller-coaster. They have, however, moved again in the focus of interest because many tumors do not sufficiently respond to immune checkpoint blockade and vaccines might help to break this resistance. The tools are now there to test this hypothesis as strategies to induce T cells more effectively, to select better targets and to combine more rationally are available and have produced encouraging results. Furthermore, evidence is accumulating that preventive cancer vaccines are promising and worth to be developed.

It has only recently become clear that the Dendritic Cell system is not only required for the induction of tumor-specific T cells but also critical in the tumor microenvironment to promote T cell immunity resulting in clinical responses.

I am very honored that top experts in these fields have accepted my invitation to come to small Erlangen for an exciting „Minisymposium“ which will promote our understanding of cancer immunotherapy as well as scientific interactions.

Kind regards



Gerold Schuler

## Programme

8.00 – 8.20 a.m.	<b>Registration</b>
8.30 – 8.45 a.m.	<b>Welcome address: Gerold Schuler</b>
8.45 – 9.15 a.m.	<b>Session 1, Chair: Günter Hämmerling</b> <b>Regulation of onco-immune pathways and their modifications by tumor cells</b> Daniel Speiser
9.15 – 9.45 a.m.	<b>Cancer immunosurveillance and preventative cancer vaccines</b> Olivera J. Finn
9.45 – 10.15 a.m.	<b>The challenge of combination immunotherapy for late stage cancer</b> Cornelis JM Melief
10.15 – 10.45 a.m.	<b>Coffee Break</b>
10.45 – 11.15 a.m.	<b>Session 2, Chair: Jan Dörrie</b> <b>On the development of personalized cancer vaccines</b> Hans-Georg Rammensee
11.15 – 11.45 a.m.	<b>Vaccination of cancer patients with Wilms tumor 1 mRNA: clinical responses, increased survival and correlation with T-cell response</b> Zwi N. Berneman
11.45 – 12.15 p.m.	<b>mRNA therapeutics: ex-vivo and in vivo modification of dendritic cells</b> Kris Thielemans
12.15 – 13.15 p.m.	<b>Lunch Break</b>
13.15 – 13.45 p.m.	<b>Session 3, Chair: Diana Duziak</b> <b>Exploiting the mutanome for tumor vaccination</b> Christoph H. Huber
13.45 – 14.15 p.m.	<b>What can we learn about dendritic cells using system approaches?</b> Joachim Schultze
14.15 – 14.45 p.m.	<b>The tumor myeloid microenvironment and its contribution to tumor immunity</b> Miriam Merad
14.45 – 15.15 p.m.	<b>Tumor -resident dendritic cells determine the fate of tumor-specific cytotoxic T cell response</b> Stefani Spranger
15.15 – 16.00 p.m.	<b>Panel Discussion</b> Speakers, Chairpersons, Invited discussants and audience
16.00 – 17.00 p.m.	<b>Coffee and Snacks</b>

## Speakers

### Zwi N. Berneman

Professor of Hematology, University of Antwerp Vaccine and Infectious Disease Institute, Faculty of Medicine and Health Sciences, University of Antwerp  
Head, Division of Hematology  
Medical Director, Center for Cell Therapy and Regenerative Medicine  
Antwerp University Hospital (UZA)

### Olivera J. Finn, PhD

Distinguished Professor, Department of Immunology, University of Pittsburgh School of Medicine

### Christoph H. Huber, MD

Professor emeritus, Klinik für Hämatologie-Onkologie-Pneumologie, Universitätsmedizin Mainz  
Founder of CIMT ([www.cimt.eu](http://www.cimt.eu)), Co-Founder of TRON ([www.tron-mainz.de](http://www.tron-mainz.de)) and BioNTech SE ([www.biontech.de](http://www.biontech.de))  
Board member Cutting Edge Technology Cluster  
Individualized Immunotherapy ([www.ci-3.de](http://www.ci-3.de))

### Prof. Cornelis Melief, MD, PhD

Emeritus professor at Leiden University,  
Chief Scientific Officer at ISA Pharmaceuticals

### Miriam Merad, MD, PhD

Endowed Professor of Cancer Immunology  
Director Precision Immunology Institute at Icahn School of Medicine at Mount Sinai (PrISM) New York

### Prof. Dr. Hans-Georg Rammensee

Department of Immunology, University Tübingen

### Prof. Dr. Joachim Schultze

Department for Genomics and Immunoregulation, LIMES-Institute, University of Bonn, PRECISE Platform for Single Cell Genomics and Epigenomics, DZNE and University of Bonn

### Prof. Daniel Speiser

Department of Oncology, University Hospital and University of Lausanne

### Stefani Spranger, PhD

Assistant Professor of Biology (MIT)  
Koch Institute for Integrative Cancer Research at MIT  
Associate Member Ragon Institute of MGH, MIT and Harvard

### Prof. Kris Thielemans, MD, PhD

Laboratory of Molecular and Cellular Therapy Department of Immunology, Medical School, Vrije Universiteit Brussel-VUB and Department of Medical Oncology, University Hospital Brussel - UZ Brussel